scPharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
scPharmaceuticals (Nasdaq: SCPH), a pharmaceutical company dedicated to enhancing patient care and reducing healthcare costs, announced that CEO John Tucker will present at the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 12:35 EDT / 5:35 GMT. The presentation will provide insights into the company's ongoing efforts to develop innovative therapies that facilitate outpatient care for acute conditions. A live webcast will be available on the company's website under the Investor Relations section.
Details
News Market Reaction – SCPH
The recorded move for SCPH in the trading session of this news was +1.62%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURLINGTON, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the Jefferies Virtual London Healthcare Conference on Wednesday, November 18 at 12:35 EDT / 5:35 GMT.
A live webcast of the presentation can be accessed under “News & Events” in the Investor Relations section of the Company’s website, www.scpharmaceuticals.com.
About scPharmaceuticals
scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.
Katherine Taudvin
scPharmaceuticals Inc., 781-301-6706
ktaudvin@scpharma.com
Investors:
Hans Vitzthum
LifeSci Advisors, 617-430-7578
hans@lifesciadvisors.com
Media:
Kate Coyle
ICR Inc., 203-682-8210
kate.coyle@icrinc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.